期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 127, 期 7, 页码 2805-2814出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI92373
关键词
-
资金
- NIH [NS032387]
- Northwestern Medicine Catalyst Fund
- Rehabilitation Research and Development Service and Medical Research Service of the Department of Veterans Affairs
- Erythromelalgia Association
Voltage-gated sodium channel (Na-V) mutations cause genetic pain disorders that range from severe paroxysmal pain to a congenital inability to sense pain. Previous studies on Na(V)1.7 and Na(V)1.8 established clear relationships between perturbations in channel function and divergent clinical phenotypes. By contrast, studies of Na(V)1.9 mutations have not revealed a clear relationship of channel dysfunction with the associated and contrasting clinical phenotypes. Here, we have elucidated the functional consequences of a Na(V)1.9 mutation (L1302F) that is associated with insensitivity to pain. We investigated the effects of L1302F and a previously reported mutation (L811P) on neuronal excitability. In transfected heterologous cells, the L1302F mutation caused a large hyperpolarizing shift in the voltage-dependence of activation, leading to substantially enhanced overlap between activation and steady-state inactivation relationships. In transfected small rat dorsal root ganglion neurons, expression of L1302F and L811P evoked large depolarizations of the resting membrane potential and impaired action potential generation. Therefore, our findings implicate a cellular loss of function as the basis for impaired pain sensation. We further demonstrated that a U-shaped relationship between the resting potential and the neuronal action potential threshold explains why Na(V)1.9 mutations that evoke small degrees of membrane depolarization cause hyperexcitability and familial episodic pain disorder or painful neuropathy, while mutations evoking larger membrane depolarizations cause hypoexcitability and insensitivity to pain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据